80 related articles for article (PubMed ID: 25185193)
1. A PLK4 inhibitor has single-agent activity in preclinical tumor models.
Cancer Discov; 2014 Sep; 4(9):OF11. PubMed ID: 25185193
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 4 inhibition: a strategy for cancer therapy?
Holland AJ; Cleveland DW
Cancer Cell; 2014 Aug; 26(2):151-3. PubMed ID: 25117704
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
Mason JM; Lin DC; Wei X; Che Y; Yao Y; Kiarash R; Cescon DW; Fletcher GC; Awrey DE; Bray MR; Pan G; Mak TW
Cancer Cell; 2014 Aug; 26(2):163-76. PubMed ID: 25043604
[TBL] [Abstract][Full Text] [Related]
4. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
5. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
[TBL] [Abstract][Full Text] [Related]
7. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
8. Drug discovery using spirooxindole cores: Success and Challenges [corrected].
Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
Eur J Med Chem; 2015 May; 95():35-40. PubMed ID: 25791677
[TBL] [Abstract][Full Text] [Related]
9. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
10. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
[TBL] [Abstract][Full Text] [Related]
11. CFI-400945 is not a selective cellular PLK4 inhibitor.
Oegema K; Davis RL; Lara-Gonzalez P; Desai A; Shiau AK
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10808-E10809. PubMed ID: 30377272
[No Abstract] [Full Text] [Related]
12. Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
Parsyan A; Cruickshank J; Hodgson K; Wakeham D; Pellizzari S; Bhat V; Cescon DW
Breast; 2021 Aug; 58():6-9. PubMed ID: 33866248
[TBL] [Abstract][Full Text] [Related]
13. Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.
Li SW; Liu Y; Sampson PB; Patel NK; Forrest BT; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Hodgson R; Beletskaya I; Mao G; Mason JM; Wei X; Luo X; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
Bioorg Med Chem Lett; 2016 Oct; 26(19):4625-4630. PubMed ID: 27592744
[TBL] [Abstract][Full Text] [Related]
14. PLK4: a link between centriole biogenesis and cancer.
Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
[TBL] [Abstract][Full Text] [Related]
15. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
[TBL] [Abstract][Full Text] [Related]
16. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
19. YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells.
Wang SW; Pan SL; Guh JH; Chen HL; Huang DM; Chang YL; Kuo SC; Lee FY; Teng CM
J Pharmacol Exp Ther; 2005 Mar; 312(3):917-25. PubMed ID: 15525795
[TBL] [Abstract][Full Text] [Related]
20. Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton.
Kazazian K; Go C; Wu H; Brashavitskaya O; Xu R; Dennis JW; Gingras AC; Swallow CJ
Cancer Res; 2017 Jan; 77(2):434-447. PubMed ID: 27872092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
